Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1

J Virol. 2000 May;74(10):4888-90. doi: 10.1128/jvi.74.10.4888-4890.2000.

Abstract

Immunization with a recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B induced strong specific T-helper cell responses in asymptomatic human immunodeficiency virus (HIV) carriers infected with subtypes B to G. This indicates that the HIV-specific T-helper immunity, which is the basis for development of antibodies and cytotoxic T lymphocytes, can be improved by both homologous and heterologous antigens. It also suggests that a particular immunogen can be effective against many different HIV strains.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / immunology*
  • Cross Reactions
  • HIV Envelope Protein gp160 / administration & dosage
  • HIV Envelope Protein gp160 / genetics
  • HIV Envelope Protein gp160 / immunology
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV-1 / classification
  • HIV-1 / immunology*
  • Humans
  • Lymphocyte Activation
  • T-Lymphocytes, Helper-Inducer / immunology*
  • Vaccination
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / immunology

Substances

  • AIDS Vaccines
  • HIV Envelope Protein gp160
  • Vaccines, Synthetic
  • VaxSyn HIV-1 (gp160) vaccine